

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Pharmacology

**Manuscript NO:** 55015

**Title:** Advances in the treatment of nonalcoholic steatohepatitis

**Reviewer's code:** 04067131

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Research Scientist

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2020-05-21

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-05-23 13:42

**Reviewer performed review:** 2020-05-29 09:30

**Review time:** 5 Days and 19 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

#### **SPECIFIC COMMENTS TO AUTHORS**

This manuscript reviews recent advances of the medicines for NASH in detail, especially with vast reports of clinical trials. It is praiseworthy for they to propose the significance of "real world applicability" in clinical trial. Perhaps, the future clinical trial design would pay more attention to the applicability of non-invasive endpoints.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Pharmacology

**Manuscript NO:** 55015

**Title:** Advances in the treatment of nonalcoholic steatohepatitis

**Reviewer's code:** 02860895

**Position:** Editorial Board

**Academic degree:** DSc, MD

**Professional title:** Chief Doctor, Professor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** United States

**Manuscript submission date:** 2020-05-21

**Reviewer chosen by:** Xiao-Quan Yu (Quit in 2020)

**Reviewer accepted review:** 2020-07-15 07:39

**Reviewer performed review:** 2020-07-26 01:24

**Review time:** 10 Days and 17 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

This is a superior review article that thoroughly describes the current development status of therapeutic medicines for nonalcoholic fatty liver disease (NAFLD). Despite a considerably critical evaluation, I couldn't find any weak points in the manuscript. Congratulations! A thing that I want to comment on this review article is only the name of this liver condition. Terminology for this type of hepatic steatosis is changing to metabolic dysfunction-associated liver disease (MAFLD). I recommend use of this newly proposed name in the review article.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Pharmacology

**Manuscript NO:** 55015

**Title:** Advances in the treatment of nonalcoholic steatohepatitis

**Reviewer's code:** 04067131

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Research Scientist

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United States

**Manuscript submission date:** 2020-05-21

**Reviewer chosen by:** Le Zhang

**Reviewer accepted review:** 2020-09-21 03:21

**Reviewer performed review:** 2020-09-21 07:31

**Review time:** 4 Hours

<b>Scientific quality</b>	<input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

No more Suggestions.